Dashboard
Manage Tickers

LIFEAtyr Pharma Inc


$ 1.76 $ -0.07 (-3.83 %)    

Monday, 17-Jun-2024 11:47:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.46 $ 2.50 (0.52 %)
DIA $ 387.71 $ 2.65 (0.69 %)
SPY $ 545.33 $ 3.26 (0.6 %)
TLT $ 93.60 $ -0.26 (-0.28 %)
GLD $ 214.18 $ -0.71 (-0.33 %)
$ 1.83
$ 1.85
$ 1.74 x 100
$ 0.00 x 0
$ 1.76 - $ 1.85
$ 1.08 - $ 2.45
141,798
na
na
$ 1.13
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atyr-pharma-announces-nasdaq-stock-ticker-symbol-change-from-life-to-atyr-effective-at-the-market-open-on-june-5-2024
aTyr Pharma Announces Nasdaq Stock Ticker ...
06/03/2024 12:27:29

aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in th...

hc-wainwright--co-reiterates-buy-on-atyr-pharma-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on aTyr...
05/14/2024 14:54:01

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

atyr-pharma-says-dsmb-recommended-ongoing-phase-3-efzo-fit-study-of-efzofitimod-continue-without-any-modifications
aTyr Pharma Says DSMB Recommended Ongoing ...
05/14/2024 12:18:47

hc-wainwright--co-reiterates-buy-on-atyr-pharma-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on aTyr...
05/03/2024 19:55:21

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

atyr-pharma-q1-eps-023-beats-024-estimate-sales-23500k-beat-2000k-estimate
aTyr Pharma Q1 EPS $(0.23) Beats $(0.24) E...
05/02/2024 20:27:04

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) b...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 20:31:18

rbc-capital-maintains-outperform-on-atyr-pharma-lowers-price-target-to-16
RBC Capital Maintains Outperform on aTyr P...
03/15/2024 16:49:46

RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19...

hc-wainwright--co-reiterates-buy-on-atyr-pharma-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on aTyr...
03/15/2024 10:20:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

recap-atyr-pharma-q4-earnings
Recap: aTyr Pharma Q4 Earnings
03/14/2024 20:15:11

atyr-pharma-q4-2023-gaap-eps-025-misses-024-estimate
aTyr Pharma Q4 2023 GAAP EPS $(0.25) Misse...
03/14/2024 20:14:09

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24)...

earnings-scheduled-for-march-14-2024
Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

atyr-pharmas-earnings-outlook
aTyr Pharma's Earnings Outlook
03/13/2024 17:01:48

hc-wainwright--co-reiterates-buy-on-atyr-pharma-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on aTyr...
02/21/2024 16:16:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price tar...

atyr-pharma-announces-expanded-access-program-eap-for-efzo-fit-clinical-trial-participants
aTyr Pharma Announces Expanded Access Prog...
02/21/2024 13:06:23

aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and deve...

atyr-pharma-presents-posters-for-neuropilin-2-in-immune-regulation-at-keystone-symposia-on-myeloid-cell-diversity
aTyr Pharma Presents Posters For Neuropili...
01/29/2024 13:18:39

 Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique...

atyr-pharma-13g-filing-shows-logos-global-management-lp-reported-a-99-stake-in-the-co-as-of-december-19-2023
ATyr Pharma 13G Filing Shows Logos Global ...
01/02/2024 17:28:06

- SEC Filing

atyr-pharma-presents-poster-demonstrating-preclinical-effects-of-efzofitimod-in-rheumatoid-arthritis-and-rheumatoid-arthritis-associated-ild-at-the-acr-convergence-2023
aTyr Pharma Presents Poster Demonstrating ...
11/13/2023 13:28:36

aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

atyr-pharma-q3-eps-020-beats-023-estimate-sales-35300k-miss-150m-estimate
aTyr Pharma Q3 EPS $(0.20) Beats $(0.23) E...
11/09/2023 21:46:43

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) b...

atyr-pharma-announces-dosing-of-first-patient-in-phase-2-efzo-connect-study-of-efzofitimod-in-patients-with-ssc-ild
aTyr Pharma Announces Dosing Of First Pati...
10/31/2023 12:05:31

aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and deve...

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
10/03/2023 18:37:58

  On Tuesday, 647 companies set new 52-week lows.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)